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Abstract
Objective The aim of this study was to investigate to
what extent atypical antipsychotics, conventional anti-
psychotics and anticholinergics are prescribed simul-
taneously in daily clinical practice in Europe.
Method A pharmaco-epidemiological study was car-
ried out in which hospital pharmacists from 45 hospi-
tals in Belgium, Denmark, France, Germany, The
Netherlands and Scotland participated. Prescription
data for 2,725 patients (mainly inpatients) who had
been using an atypical antipsychotic for more than
6 weeks were analysed.
Main outcome measure The frequencies of simulta-
neous prescription of atypical antipsychotics with other
antipsychotics and/or anticholinergics.
Results In this sample of patients with an atypical
antipsychotic 42.1% was prescribed another antipsy-
chotic (24.1% if low-potent antipsychotics were not
included in the analysis) and 30.1% was prescribed an
anticholinergic. In total 47.1% of patients were pre-
scribed an atypical antipsychotic without any other
antipsychotic or anticholinergic.
Conclusion It is common practice to prescribe a com-
bination of atypical antipsychotics and conventional
antipsychotics and/or anticholinergics. This suggests
that monotherapy involving an atypical antipsychotic is
not considered to be an adequate treatment for a sub-
stantial number of patients in clinical practice.
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Introduction
All antipsychotics are solely registered for use as mono-
therapy. The prescription of two or more antipsychotics
simultaneously, also called antipsychotic polypharmacy,
has no empirical foundation [1]. However, in the past
antipsychotic polypharmacy with two conventional
(‘early generation’) antipsychotics was frequently prac-
tised with reported frequencies ranging from approxi-
mately 10–69% [2]. In the last years the conventional
antipsychotics are increasingly replaced by the atypical
(‘second generation’) antipsychotics. Few studies from
the UK and the US have focused on antipsychotic poly-
pharmacy with atypical antipsychotics and reported fre-
quencies ranging from 13% to 68% [3–7].
We carried out a pharmaco-epidemiological study to
atypical antipsychotic polypharmacy and included data
of patients of several psychiatric hospitals in various
European countries. Additionally, we also focused on
the co-prescription of anticholinergic drugs. There is
considerable evidence that atypical antipsychotics
cause fewer extrapyramidal side effects than conven-
tional antipsychotics [8]. Therefore, there should be
less need for anticholinergic co-medication to be pre-
scribed with the atypicals.
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123This European study was conducted to investigate to
what extent atypical antipsychotics, conventional anti-
psychotics and anticholinergics are being prescribed
simultaneously in daily clinical practice.
Method
The study was carried out with the co-operation of
members of the ‘European Pharmacists for Psychiatry
and Neurology’ (EPPN), an organisation of hospital
pharmacists working in psychiatry and neurology. All
participating hospital pharmacists were working in
psychiatric hospitals. Data were collected between
November 1998 and October 1999. In that period the
hospital pharmacists screened their hospital pharmacy
database on one single day for patients who had been
using an atypical antipsychotic for a minimum of
6 weeks. The 6-week period was chosen so that titra-
tion to the atypical antipsychotic should have been
completed. No restrictions were imposed with regard
to age and diagnosis.
The following data were collected for each patient
included: age, sex, type and dose of the atypical(s) and,
if prescribed, type and dose of conventional antipsy-
chotics (maximum of four) and the type of anticho-
linergics (maximum of four). ‘‘As needed’’ (PRN)
medication was considered as ‘‘used’’ medication. The
doses of antipsychotic depot-medications were recal-
culated to daily oral doses [9]. All data were checked
for improbable doses, duplication of patients and other
errors.
Median doses of the antipsychotics are given, be-
cause of positively skewed distributions. The frequen-
cies with which antipsychotic polypharmacy was
practised and anticholinergics were prescribed are
calculated for the total group of patients and per
individual atypical antipsychotic.
Conventional antipsychotics with a chlorpromazine
equivalent dose of more than 40 mg (compared to
100 mg chlorpromazine) are considered to be low po-
tency drugs [10, 11]. The frequencies with which anti-
psychotic polypharmacy was practised are calculated
with and without the low-potent antipsychotics.
Results
Hospital pharmacists from six West European coun-
tries participated: Belgium, Denmark, France, Ger-
many, The Netherlands and Scotland. In total, data
were received for 2,765 patients. Of these, 40 patients
(1.5%) were excluded for the following reasons: pa-
tients mentioned twice (n = 10), no atypical antipsy-
chotic prescribed (n = 8), improbably low clozapine
doses (n = 5) and other errors (n = 17).
Table 1 shows details of the participating countries
and patients. Most patients came from Belgium
(40.9%), followed by The Netherlands (26.2%) and
France (16.5%).
Table 2 shows the frequencies with which the atyp-
ical antipsychotics were prescribed, the median dose,
the frequencies with which of antipsychotic polyphar-
macy (with and without the low-potent conventional
antipsychotics) was practised, the frequencies with
which anticholinergics were administrated and the
frequencies of no co-prescription of antipsychotics or
anticholinergics.
Risperidone was prescribed most often (40.2%),
followed by clozapine (25.1%), olanzapine (20.6%)
and others (in total 14.1%). For 65 patients (2.4%) 2
atypical antipsychotics were prescribed; the combina-
tions used most were clozapine/risperidone (n = 18),
olanzapine/risperidone (n = 12) and sulpiride/risperi-
done (n = 11). In our population of patients using an
atypical, antipsychotic polypharmacy was prescribed in
42.1% of cases. Of patients receiving antipsychotic
polypharmacy 31.7%, 8.5%, 1.3% and .6% were pre-
scribed two, three, four, and ﬁve or more antipsy-
chotics respectively.
Table 3 shows the antipsychotics prescribed
concurrently with the atypicals. The conventional
antipsychotics prescribed most often were levome-
promazine, haloperidol, prothipendyl, cyamemazine
and zuclopentixol. When the low-potent conventional
Table 1 Number of hospitals
and patients included in the
participating countries with
the mean age of patients and
the percentages of male
patients
Country Number of hospitals (%) Number of patients (%) Mean age (sd) % of males
Belgium 19 (42.2%) 1115 (40.9%) 47.9 (15.6) 59%
The Netherlands 5 (11.1%) 715 (26.2%) 46.1 (17.9) 54%
France 10 (22.2%) 449 (16.5%) 42.3 (14.5) 61%
Denmark 4 (8.9%) 217 (8.0%) 48.1 (16.4) 52%
Scotland 6 (13.3%) 183 (6.7%) 45.8 (17.7) 51%
Germany 1 (2.2%) 46 (1.7%) 38.5 (13.9) 60%
Total 45 (100%) 2725 (100%) 46.2 (16.4) 57%
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of the patients was prescribed antipsychotic
polypharmacy.
In total 30.1% of the patients were prescribed an
anticholinergic drug. The anticholinergics prescribed
most often were biperiden (28.3%), procyclidine
(19.9%), trihexyphenidyl (16.7%) and tropatepine
(13.4%).
In total 47.1% of the patients are prescribed the
atypical antipsychotic without any other antipsychotic
or anticholinergic, 22.8% are prescribed an atypical
plus one or more other antipsychotics, 10.8% are given
an atypical plus an anticholinergic and 19.3% an
atypical plus an anticholinergic and one or more other
antipsychotics.
Discussion
This European study clearly shows that it is common
clinical practice to prescribe an atypical antipsychotic
and one or more other antipsychotics simultaneously.
Low-potent antipsychotics may be added to an atypical
antipsychotic mainly because of their sedative, anxio-
lytic and anticholinergic properties, rather than be-
cause of their antipsychotic properties. Even when the
low-potent conventional antipsychotics are not in-
cluded in the analysis, we found that antipsychotic
polypharmacy was prescribed for almost a quarter of
the patients. Additionally, we did not expect to ﬁnd
that almost a third of the patients were prescribed an
anticholinergic in addition to the atypical drug. The
results of this study imply that more than half (52.9%)
of the patients are not being treated in the way
according to the psychiatric handbooks and guidelines:
The atypical is frequently combined with another
antipsychotic and/or an anticholinergic.
Several studies have shown that antipsychotic poly-
pharmacy with two conventional antipsychotics was in
Table 2. Details of the atypical antipsychotics prescribed: their
frequencies; median dose; the frequencies of patients prescribed
antipsychotic polypharmacy (with and without low-potent
antipsychotics) and anticholinergics; the frequencies of no co-






















Risperidone 1095 (40.2%) 4.0 45.1 24.7 36.5 42.0
Clozapine 683 (25.1%) 400.0 31.2 18.9 24.5 57.7
Olanzapine 562 (20.6%) 15.0 37.0 22.1 20.3 56.2
Sulpiride 133 (4.9%) 300.0 49.2 25.8 31.1 41.7
Amisulpride 132 (4.8%) 600.0 54.1 23.3 45.9 28.6
Sertindole 37 (1.4%) 16.0 62.2 24.3 27.0 29.7
Quetiapine 16 (0.6%) 550.0 50.0 12.5 12.5 43.8
Zotepine 2 (0.1%) 225.0 0 0 0 100
Two atypicals 65 (2.4%) ** *** *** 40.0 ****
Total 2725 (100%) – 42.1% 24.4% 30.1% 47.1%
* See Table 3 for the classiﬁcation of the low-potent antipsychotics
** Total median dose not calculated
*** By deﬁnition 100%
**** By deﬁnition 0%
Table 3 The frequencies and median doses antipsychotics


























Second atypical 4.2% –
Total 100.0% –
* Considered as low-potent antipsychotic
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123frequent use in clinical practice [2]. Others have shown
that fairly large numbers of patients (ranging from
18.5% to 56%) are being prescribed a therapy that
combines clozapine with a conventional antipsychotic
[12–14]. Recently, a few studies have focused on anti-
psychotic polypharmacy with the atypical antipsy-
chotics, with reported frequencies ranging from 13% to
68% [3–7]. There could be several reasons to explain
this large variation in co-prescribing such as the deﬁ-
nition of antipsychotic polypharmacy, whether inpa-
tients or outpatients were included, stage of the
disease, the differences in prescription patterns be-
tween countries and hospitals and different use of
guidelines.
We consider several hypotheses for the relatively
high rate of antipsychotic polypharmacy involving
atypicals. First of all, it could be that the patients with
an inadequate treatment response to one antipsychotic
are treated with combinations of antipsychotics,
including the atypical antipsychotics. However, there
are hardly any studies that show that antipsychotic
polypharmacy is effective in patients who do not re-
spond to one antipsychotic [1].
Secondly, it is also possible that antipsychotic poly-
pharmacy is continued although the patient shows no
improvement because psychiatrists are hesitant to dis-
continue any medication in patients with persistent
psychotic symptoms.
Thirdly, it could be that in some patients the rec-
ommended doses of the atypical antipsychotics are too
low to be effective and that adding a second antipsy-
chotic is in fact a dose-increase strategy. In such cases,
however, a higher dose of one particular atypical might
be just as effective.
Fourthly, when switching between two antipsychot-
ics it is common to titrate the ﬁrst drug downwards
while simultaneously titrating the second drug up-
wards. If the patient responds halfway through the
titrating process the clinician might decide to continue
both antipsychotics—a situation referred to as ‘‘the
cross-titration trap’’ [15]. Our study included only pa-
tients who had been using an atypical antipsychotic for
more than 6 weeks, so the titrating process would
normally have been completed.
It is remarkable that the potential risks of antipsy-
chotic polypharmacy have received limited research
attention [16]. However, Waddington et al. [17] found
that antipsychotic polypharmacy is associated with re-
duced survival among patients with schizophrenia.
Centorrino et al. [16] reports that the risk of adverse
effects is 56% higher with antipsychotic polypharmacy.
There have been previous reports of anticholinergics
being added to atypical antipsychotics. Of patients
using clozapine 19% [12] and 37% [14] were also
prescribed anticholinergics. Anticholinergics were ad-
ded to 54.9% of patients using atypical antipsychotics
[3]. These numbers are in line with our ﬁnding (30.1%).
The prescription of this combined therapy could be
attributed to the use of a second, almost always con-
ventional, antipsychotic (19.3%), which might induce
extrapyramidal symptoms. But nevertheless, 10.8% of
patients are prescribed an atypical antipsychotic in
combination with an anticholinergic without any other
(conventional) antipsychotics. Minzenberg et al. [18]
studied the effects of anticholinergic properties of
psychiatric medications and found clinically signiﬁcant
effects on memory and complex attention.
The frequencies of atypical polypharmacy in the
separate countries range between 26.1% (Germany)
and 49.1% (Belgium), without the low-potent anti-
psychotics it varies between 17.1% (Denmark) and
31.6% (Belgium). However, these numbers should be
appraised cautiously because this study was not pri-
mary set up to detect differences between the various
countries (some countries are under represented).
Furthermore, the study does not allow to draw
inferences about differences between the various
atypicals in antipsychotic polypharmacy and anticho-
linergic use. These differences could easily be biased as
a result of the different introduction data of the atyp-
icals in the diverse countries. For example, at the
moment of data-collection olanzapine and sertindole
had been introduced very recently in most countries,
quetiapine was available only in Scotland and zotepine
was used only in a clinical trial.
Nevertheless, the similarity between the frequencies
with which antipsychotic polypharmacy is prescribed
for the various atypicals (excluding quetiapine and
zotepine, on account of their low frequencies) is
remarkable: Excluding low-potent antipsychotics the
frequencies range from 18.9% to 25.8%.
The study however has its limitations.
First of all, the population included is not a random
sample from Western European countries that partic-
ipated. Therefore, hypothetically it could be argued
that the results were biased because only hospitals
practising extremely high rates of antipsychotic poly-
pharmacy were included. However, it is unlikely that
only such hospitals were selected.
Secondly, we estimate, on the basis of the informa-
tion obtained from the participating hospitals, that
90% of the data are from inpatients. The symptom-
atology of inpatients may be more severe than that of
outpatients, and such patients may be prescribed
antipsychotic polypharmacy more frequently than
outpatients [3].
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medication. This may have heightened our results
somewhat but cannot explain the frequent prescription
of antipsychotic polypharmacy. A major advantage of
this study is the large number of patients included and
the differentiation made between high- and low-potent
antipsychotics. This makes extrapolation more feasible.
Conclusion
It is common practice to prescribe a combination of
atypical and conventional antipsychotics. Furthermore,
the use of atypical antipsychotics does rule out the use
of anticholinergics. On the contrary, atypical antipsy-
chotics are often prescribed in combination with anti-
cholinergics. Apparently, monotherapy involving the
atypicals is not considered to be an effective therapy
for a substantial number of patients in clinical practice.
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